The International Olympic Committee rolled out a new eligibility rule last week that sparked fresh debate. Athletes competing in women’s events will now undergo screening for the SRY gene, a marker tied to male sex determination. The decision aims to clarify who qualifies as female, but it opens a tangle of scientific and ethical questions that won’t settle easily.
This isn’t just about fairness in competition. It’s about how we define biological sex, what advantages actually exist, and whether sport can ever offer a truly level playing field. The conversation matters to athletes, families, and communities wrestling with inclusion and equity in public life.
Sex determination involves more than a simple gene test. In humans, the SRY gene sits on the Y chromosome and triggers testis development in early embryos. Those testes produce androgens like testosterone, which drive male physical traits. Males typically carry one X and one Y chromosome, while females have two X chromosomes. That’s the textbook version, but biology rarely follows textbooks perfectly.
Over the years, sex testing in sport evolved from physical inspections to chromosome analysis. Early methods were slow and sometimes misdiagnosed athletes with chromosomal variations. The new SRY test detects the gene directly, which sounds straightforward until you examine the exceptions. The SRY gene activates dozens of other genes that either promote testis development or block ovary formation. Variations in any of these genes can produce surprising outcomes.
Some women carry an inactive SRY gene that never triggers testis development. Others have a working SRY gene and testes that produce androgens, but their bodies can’t respond to male hormones due to receptor issues. The SRY test would flag these women as biological males and exclude them from competition. Meanwhile, some men carry two X chromosomes without SRY, yet other genetic variants override its absence. Under the current test, they’d qualify for women’s events. The scientist who co-discovered the SRY gene has warned that this approach misdiagnoses athletes with variant sex genes and chromosomes.
The International Olympic Committee will need to account for these variations if the test is to work fairly. Genetics doesn’t deliver neat categories, and policy has to catch up.
Physiological studies over decades confirm that men have, on average, larger hearts, more efficient lung function, and greater muscle mass than women. These traits exist on a spectrum with plenty of overlap. Tall women and short men are common enough. But statistically, men tend to be bigger and stronger.
Recent research suggests these differences run deeper than we thought. A 2017 study found that nearly one-third of our roughly 20,000 genes behave differently in men and women. These differences show up not just in reproductive organs but in hearts, lungs, brains, and muscle tissue. The same patterns appear in monkeys and emerge before birth. In three types of muscle cells alone, 2,100 genes function differently between sexes.
Androgens have traditionally been credited with these differences, especially during embryonic development, childhood, and puberty. But experiments with mice that had genetically altered sex chromosomes revealed that some aspects of physiology, like fat and energy metabolism, are linked to the number of X chromosomes rather than SRY or hormones. The Y chromosome also provides ongoing health benefits, evident when aging men lose it in some cells.
Sex differences in tissue function are more profound than hormones alone can explain. That complicates any discussion about transgender athletes.
The evidence here is less clear and often contradictory. Transitioning from male to female involves hormone replacement therapy, which suppresses androgens and introduces estrogen. This process changes the body significantly. Trans women develop breasts, gain body fat, and lose muscle mass. Testicular tissue atrophies.
Trans girls may also take puberty blockers before male puberty begins. These medications prevent the surge of androgens that cause irreversible physical changes. The question of whether trans women athletes hold a physical advantage over cisgender women depends on understanding what irreversible changes occurred before and during puberty, plus any non-hormonal differences that might affect performance.
Studies show mixed results depending on when and how someone transitioned. Some research indicates trans women retain longer limbs, stronger hand grip, and greater muscle mass on average. But after two years of hormone therapy, cardiac and respiratory function aligns with cisgender women. We lack data on gene activity in trans women athletes, so key questions remain unanswered. Do the 2,100 genes in muscle cells shift to a female activity pattern? Do genes on the Y chromosome protect heart and kidney function? Does the absence of a second X chromosome improve fat and energy metabolism?
More research would likely confirm that trans women who experienced male puberty retain some advantages in organ size and function that hormone therapy doesn’t reverse. Even if transition happened before puberty, non-hormonal effects from early development probably create subtle performance differences. These differences may be small, but in elite sport, where medals are won by hundredths of a second, cisgender women athletes argue they matter.
The ban on transgender athletes stumbles over human variability. Cisgender athletes already show great physical variation in the very traits that make them excel. Androgen levels vary widely among cisgender women, prompting some to call for bans on hyperandrogenized women or mandated hormone ceilings. Do we also ban exceptionally tall women from basketball? Where does regulation stop making sense?
Sport participation matters for health and social connection. For some trans women, it’s life-changing in the best sense. That makes discussing alternatives crucial. Open competitions alongside the Olympics or categories based on criteria other than sex deserve serious consideration.
Maybe we need to accept that sport never offers a truly level playing field. Elite athletes are outliers in many physical and physiological traits. They possess rare combinations of height, lung capacity, muscle fiber composition, and cardiovascular efficiency that most people will never approach. Is that fair to the rest of us? Probably not, but we celebrate it anyway.
The International Olympic Committee’s new rule reflects genuine concern about fairness, but it also exposes how imperfect our tools are for navigating complex biology. Genetics doesn’t divide neatly into two boxes, and neither do the lives of athletes who train for years to compete. This debate will continue because the questions are hard and the stakes are high for everyone involved.
